Regeneron Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Okay. Good morning, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, Senior Biopharma Analyst here at Barclays. I'm pleased to welcome Regeneron Pharmaceuticals on the stage. It's been a while since we've seen you guys in person, really glad to have you. We have both Marion McCourt, EVP of Commercial; and Bob Landry, CFO.
Before we jump into the questions here, Bob is going to make some opening remarks and some forward-looking statements.
Yes. Great. Carter, thank you for inviting us. And again, a little surreal for Marion and myself to be on stage after 2-plus years. Thanks just to certainly give it a go and get into Q&A.
So from a forward-looking statement point of view, I'd like to remind everybody that the statements Marion and I will be making today about Regeneron contain risks and uncertainties. And again, I encourage everyone to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
